Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
28 jul 2016 - 22:00
Statutaire naam
Galapagos NV
Titel
Focus on filgotinib and cystic fibrosis
Bericht
First half-year financial results:
Revenues €48.8 M, an increase of €11.9 M compared to H1 2015
Operating loss €24.3 M, an improvement of € 11.3 M compared to H1 2015
Cash on 30 June 2016 of €968.5 M
Ruling for reduced tax rate on filgotinib income
Solid execution of R&D programs
Successful conclusion of regulatory discussions for filgotinib in rheumatoid arthritis Phase 3 program
Expansion of cystic fibrosis collaboration with AbbVie
Favorable topline Phase 1 results in cystic fibrosis and osteoarthritis
Nomination of two fully proprietary pre-clinical candidates in inflammation
Webcast presentation tomorrow 29 July at 14.00 CET/8 AM ET, www.glpg.com, +32 2 404 0659, code 4067587
Mechelen, Belgium; 28 July 2016, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces its unaudited first half-year results, which are further detailed in an online H1 2016 report published on the Galapagos website, www.glpg.com.
Galapagos reported financial results in line with expectations and solid progress in its R&D programs. The filgotinib FINCH Phase 3 program in rheumatoid arthritis (RA) is expected to start shortly and preparations for the Phase 3 program in Crohn's disease and the Phase 2/3 program in ulcerative colitis are underway for a start later this year as well. At its annual R&D update Galapagos announced substantial progress in its cystic fibrosis programs with AbbVie, conducting several Phase 1 and 2 clinical studies. Finally, the rest of the pipeline made encouraging progress with the start of the FLORA Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis, the start of a Phase 1 study with novel monoclonal antibody MOR106, encouraging osteoarthritis biomarker data for GLPG1972 in Phase 1 and the nomination of two fully proprietary pre-clinical candidates in idiopathic pulmonary fibrosis and atopic dermatitis. With regard to the Gilead filgotinib collaboration, Galapagos received a confirmation ruling from the Belgian Ministry of Finance that the col
Datum laatste update: 28 juli 2024